173 related articles for article (PubMed ID: 33859803)
1. Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.
Deng W; Chen X; Jiang K; Song X; Huang M; Tu ZC; Zhang Z; Lin X; Ortega R; Patterson AV; Smaill JB; Ding K; Chen S; Chen Y; Lu X
ACS Med Chem Lett; 2021 Apr; 12(4):647-652. PubMed ID: 33859803
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors.
Nie W; Lu Y; Pan C; Gao J; Luo M; Du J; Wang J; Luo P; Zhu H; Che J; He Q; Dong X
Bioorg Chem; 2022 Apr; 121():105673. PubMed ID: 35217375
[TBL] [Abstract][Full Text] [Related]
4. Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S
Schwarz M; Kurkunov M; Wittlinger F; Rudalska R; Wang G; Schwalm MP; Rasch A; Wagner B; Laufer SA; Knapp S; Dauch D; Gehringer M
J Med Chem; 2024 Apr; 67(8):6549-6569. PubMed ID: 38604131
[TBL] [Abstract][Full Text] [Related]
5. 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.
Mo C; Zhang Z; Guise CP; Li X; Luo J; Tu Z; Xu Y; Patterson AV; Smaill JB; Ren X; Lu X; Ding K
ACS Med Chem Lett; 2017 May; 8(5):543-548. PubMed ID: 28523108
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors.
Wang M; Lan L; Wang YW; Zhang JY; Shi L; Sun LP
Bioorg Med Chem; 2023 May; 87():117298. PubMed ID: 37196426
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.
Chen X; Li H; Lin Q; Dai S; Qu L; Guo M; Zhang L; Liao J; Wei H; Xu G; Jiang L; Chen Y
Eur J Med Chem; 2024 Mar; 268():116281. PubMed ID: 38432058
[TBL] [Abstract][Full Text] [Related]
8. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of a dual-warhead covalent inhibitor of FGFR4.
Chen X; Li H; Lin Q; Dai S; Yue S; Qu L; Li M; Guo M; Wei H; Li J; Jiang L; Xu G; Chen Y
Commun Chem; 2022 Mar; 5(1):36. PubMed ID: 36697897
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.
Shao M; Chen X; Yang F; Song X; Zhou Y; Lin Q; Fu Y; Ortega R; Lin X; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2022 Mar; 65(6):5113-5133. PubMed ID: 35271262
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract][Full Text] [Related]
12. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
[TBL] [Abstract][Full Text] [Related]
13. Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges.
Chen X; Huang Y; Chen B; Liu H; Cai Y; Yang Y
Eur J Med Chem; 2024 Jan; 263():115947. PubMed ID: 37976704
[TBL] [Abstract][Full Text] [Related]
14. Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors.
McAulay K; Hoyt EA; Thomas M; Schimpl M; Bodnarchuk MS; Lewis HJ; Barratt D; Bhavsar D; Robinson DM; Deery MJ; Ogg DJ; Bernardes GJL; Ward RA; Waring MJ; Kettle JG
J Am Chem Soc; 2020 Jun; 142(23):10358-10372. PubMed ID: 32412754
[TBL] [Abstract][Full Text] [Related]
15. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
Wu D; Guo M; Philips MA; Qu L; Jiang L; Li J; Chen X; Chen Z; Chen L; Chen Y
PLoS One; 2016; 11(9):e0162491. PubMed ID: 27618313
[TBL] [Abstract][Full Text] [Related]
16. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
[TBL] [Abstract][Full Text] [Related]
17. Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.
Lin X; Yosaatmadja Y; Kalyukina M; Middleditch MJ; Zhang Z; Lu X; Ding K; Patterson AV; Smaill JB; Squire CJ
ACS Med Chem Lett; 2019 Aug; 10(8):1180-1186. PubMed ID: 31413803
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.
Fairhurst RA; Knoepfel T; Buschmann N; Leblanc C; Mah R; Todorov M; Nimsgern P; Ripoche S; Niklaus M; Warin N; Luu VH; Madoerin M; Wirth J; Graus-Porta D; Weiss A; Kiffe M; Wartmann M; Kinyamu-Akunda J; Sterker D; Stamm C; Adler F; Buhles A; Schadt H; Couttet P; Blank J; Galuba I; Trappe J; Voshol J; Ostermann N; Zou C; Berghausen J; Del Rio Espinola A; Jahnke W; Furet P
J Med Chem; 2020 Nov; 63(21):12542-12573. PubMed ID: 32930584
[TBL] [Abstract][Full Text] [Related]
20. Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.
Fairhurst RA; Knoepfel T; Leblanc C; Buschmann N; Gaul C; Blank J; Galuba I; Trappe J; Zou C; Voshol J; Genick C; Brunet-Lefeuvre P; Bitsch F; Graus-Porta D; Furet P
Medchemcomm; 2017 Aug; 8(8):1604-1613. PubMed ID: 30108871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
